The Impact of Exempting Medical Providers from Malpractice Liability
The Impact of Exempting Medical Providers from Malpractice Liability
批准号:
10634734
负责人:
MICHAEL D. FRAKES
金额:
$32.33万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
未结题
起止时间:
2015-06-15 至 2025-05-31
关键词:
AdherenceAgeAgingAmbulatory CareAttentionCardiovascular DiseasesCaringCodeCommunitiesContractsDataData SetDatabase Management SystemsDefensive MedicineDiabetes MellitusDiagnostic testsDimensionsDisclosureDiseaseEnvironmentEquilibriumEvaluationEventFamilyFrightHealth Care CostsHealthcareHealthcare SystemsImmunizeInstitutionLife Cycle StagesLiteratureMalignant NeoplasmsMalpracticeMeasuresMedicalMedical LiabilitiesMethodologyMilitary PersonnelNegligenceOpiate AddictionOpioidPatientsPatternPharmacy facilityPhysician-Patient RelationsPhysiciansPlayPoliciesPopulationPrivatizationProceduresProtocols documentationProviderQuality of CareResearchRoleServicesSideSystemTestingVariantVeterans Health AdministrationWorkactive dutyage relatedbasecare deliverycare systemscomparison groupcostfascinateinpatient serviceinterestmedical attentionmedical malpracticemilitary health systemopioid misuseopioid useprescription monitoring programprescription opioidpressureprovider behaviorretireeservice memberstemsurgical risktreatment and outcometreatment group
中文摘要
点击翻译按钮获取中文摘要
英文摘要
OTHER PROJECT INFORMATION – Project Summary/Abstract
THE IMPACT OF EXEMPTING MEDICAL PROVIDERS FROM MALPRACTICE LIABILITY
Among the most controversial aspects of the U.S. health care system are the impacts of the medical
malpractice system on patient treatments and health care costs. Defensive medicine is an unintended effect of
the liability system in which physicians order extraneous tests, procedures and other services as a result of
fears over medical liability. The debate continues, however, regarding just how large these costs really are.
Missing from the literature's attempts to resolve this debate has been a true “treatment” group of medical
encounters with respect to which there is no liability recourse at all in the event of negligent care. We aim to
further the analysis begun under R01AG049898, in which we drew on institutional features of the Military
Health System (MHS) to estimate the effects of immunizing providers from liability, facilitating an
unprecedented assessment of the full extent of defensive medicine operating in our system. We propose to
continue this research to push the literature beyond its present focus on inpatient care and to place the effects
of liability in perspective by comparing liability's effects with other approaches, especially demand-side
approaches, to regulating medical encounters. Our focus will be on investigating the impacts of certain policy
levers on age-related diseases such as cardiovascular disease, diabetes, and cancer.
The proposed continuation will address four aims. First we will explore the impact of medical liability pressure
on “high-value” outpatient care, while placing these estimates into perspective by likewise exploring effects on
the receipt of “low-value” care (drawing on high- and low-value measures currently emphasized in the medical
literature). Second, drawing on a unique feature of the MHS data, we propose to compare the effects on high-
and low-value care receipt stemming from the medical liability system – a classic supply-side approach to
regulating provider behavior – with those resulting from a classic demand-side approach to regulating the
physician-patient relationship: information disclosure to patients. Third, we will place independent emphasis on
one of the key dimensions of comparison necessary to execute the liability analysis – that is, the difference in
quality and quantity of care provided on the base through a coordinated direct-delivery system with that
provided off the base through the MHS's purchased-care system. Fourth, we will explore aspects of each of
the above aims specifically in the context of opioid use among the MHS population, while comparing the
effects of liability pressure and information disclosure on opioid use with the effects of one of the most oft-
discussed stated-based approaches to regulating opioid use: Prescription Drug Monitoring Programs.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
Is great information good enough? Evidence from physicians as patients.
伟大的信息就足够好吗?来自医生和患者的证据。
DOI:
10.1016/j.jhealeco.2020.102406
发表时间:
2021-01
期刊:
Journal of health economics
影响因子:
3.5
作者:
[Frakes M, Gruber J, Jena A]
通讯作者:
Jena A
Public and Private Options in Practice: The Military Health System.
实践中的公共和私人选择:军事卫生系统。
DOI:
10.1257/pol.20210625
发表时间:
2023
期刊:
American economic journal. Economic policy
影响因子:
--
作者:
[Frakes,MichaelD, Gruber,Jonathan, Justicz,Timothy]
通讯作者:
Justicz,Timothy
The Impacts of Enhanced Drug-Patent Examination
-
批准号:10587507
-
项目类别:
-
资助金额:$31.66万
-
财政年份:2023
-
负责人:MICHAEL D. FRAKES
-
依托单位:
The Impact of Exempting Medical Providers from Malpractice Protection
-
批准号:8862791
-
项目类别:
-
资助金额:$31.6万
-
财政年份:2015
-
负责人:MICHAEL D. FRAKES
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: